2.89

1.23% +0.035

After Hours: 2.91 0.02 +0.69%

Allogene Therapeutics Inc (ALLO)

Overview News Price History Option Chain Discussions Forecast

Allogene Therapeutics Inc stock is currently priced at $2.89, with a 24-hour trading volume of 2.43M. It has seen a +1.23% increased in the last 24 hours and a -31.35% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.90 pivot point. If it approaches the $2.80 support level, significant changes may occur.

Previous Close:

$2.855

Open:

$2.87

24h Volume:

2.43M

Market Cap:

$493.39M

Revenue:

$95,000

Net Income/Loss:

$-327.27M

P/E Ratio:

-1.1796

EPS:

-2.45

Net Cash Flow:

$-239.25M

1W Performance:

-16.71%

1M Performance:

-31.35%

6M Performance:

+9.47%

1Y Performance:

-46.78%

1D Range:

$2.75

$2.93

52W Range:

$2.23

$6.89

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name

Allogene Therapeutics Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

415-640-5325

Address

210 East Grand Avenue, South San Francisco

Employee

Twitter

@AllogeneTx

Next Earnings Date

2024-05-14

Latest SEC Filings

ALLO's Discussions on Twitter

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy
Jun-03-22	Initiated	Robert W. Baird	Neutral
Feb-28-22	Reiterated	B. Riley Securities	Buy
Oct-20-21	Initiated	Cowen	Outperform
Oct-08-21	Downgrade	Goldman	Buy → Neutral
Oct-08-21	Downgrade	Stifel	Buy → Hold
Sep-23-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-21-21	Resumed	Jefferies	Buy
May-20-21	Upgrade	Truist	Hold → Buy
May-14-21	Initiated	B. Riley Securities	Buy
Jan-26-21	Upgrade	Stifel	Hold → Buy
Dec-10-20	Resumed	H.C. Wainwright	Buy
Nov-24-20	Initiated	BofA Securities	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Outperform
Jun-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-29-20	Reiterated	H.C. Wainwright	Buy
May-19-20	Upgrade	ROTH Capital	Neutral → Buy
May-15-20	Upgrade	Guggenheim	Neutral → Buy
May-14-20	Reiterated	H.C. Wainwright	Buy
May-14-20	Downgrade	SunTrust	Buy → Hold
Apr-13-20	Initiated	SunTrust	Buy
Mar-13-20	Initiated	H.C. Wainwright	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-24-20	Initiated	Berenberg	Hold
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Nov-04-19	Initiated	Canaccord Genuity	Buy
Aug-09-19	Initiated	BTIG Research	Buy
Jun-05-19	Initiated	ROTH Capital	Neutral
May-31-19	Initiated	Guggenheim	Neutral
May-23-19	Initiated	Stifel	Hold
Mar-29-19	Initiated	Piper Jaffray	Overweight

View All

Allogene Therapeutics Inc Stock (ALLO) Latest News

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

GlobeNewswire Inc.

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation

Benzinga

How Allogene (ALLO) Stock Stands Out in a Strong Industry

Zacks Investment Research

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Zacks Investment Research

Allogene Therapeutics Inc Stock (ALLO) Financials Data

Allogene Therapeutics Inc (ALLO) Revenue 2024

ALLO reported a revenue (TTM) of $95.00 thousand for the quarter ending December 31, 2023, a -39.10% decline year-over-year.

Allogene Therapeutics Inc (ALLO) Net Income 2024

ALLO net income (TTM) was -$327.26 million for the quarter ending December 31, 2023, a +3.86% increase year-over-year.

Allogene Therapeutics Inc (ALLO) Cash Flow 2024

ALLO recorded a free cash flow (TTM) of -$239.25 million for the quarter ending December 31, 2023, a -6.00% decrease year-over-year.

Allogene Therapeutics Inc (ALLO) Earnings per Share 2024

ALLO earnings per share (TTM) was -$2.12 for the quarter ending December 31, 2023, a +8.62% growth year-over-year.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.